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Objective: The aim of the present study was to encapsulate vancomycin in different 
liposomal formulations and compare the in vitro antimicrobial activity against 
Staphylococcus aureus biofilms.
Methods: Large unilamellar vesicles of conventional (LUV VAN), fusogenic (LUVfuso VAN), 
and cationic (LUVcat VAN) liposomes encapsulating VAN were characterized in terms of 
size, polydispersity index, zeta potential, morphology, encapsulation efficiency (%EE) 
and in vitro release kinetics. The formulations were tested for their Minimum Inhibitory 
Concentration (MIC) and inhibitory activity on biofilm formation and viability, using 
methicillin-susceptible S. aureus ATCC 29213 and methicillin-resistant S. aureus ATCC 
43300 strains.
Key Findings: LUV VAN showed better %EE (32.5%) and sustained release than LUVfuso 
VAN, LUVcat VAN, and free VAN. The formulations were stable over 180 days at 4°C, 
except for LUV VAN, which was stable up to 120 days. The MIC values for liposomal 
formulations and free VAN ranged from 0.78 to 1.56 µg/ml against both tested strains, 
with no difference in the inhibition of biofilm formation as compared to free VAN. However, 
when treating mature biofilm, encapsulated LUVfuso VAN increased the antimicrobial 
efficacy as compared to the other liposomal formulations and to free VAN, demonstrating 
a better ability to penetrate the biofilm.
Conclusion: Vancomycin encapsulated in fusogenic liposomes demonstrated enhanced 
antimicrobial activity against mature S. aureus biofilms.
Keywords: fusogenic liposomes, cationic liposomes, Staphylococcus aureus, vancomycin, biofilm
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InTrODUCTIOn
Staphylococcus aureus (S. aureus) is a Gram-positive 
microorganism responsible for the majority of nosocomial and 
community-acquired infections. Notably, S. aureus infections 
remain a global public health issue highly costly for the healthcare 
system, with increasing morbidity and mortality rates worldwide 
(Chakraborty et al., 2012; Honary et al., 2013; Elkhodairy et al., 
2014; Holland et al., 2014). Today, over 90% of S. aureus strains 
are found to be resistant to methicillin (methicillin resistant 
S. aureus—MRSA), penicillin, aminoglycosides, macrolides, 
lincosamides, and other beta-lactams (Chakraborty et al., 2012; 
Muppidi et al., 2012; Sande et al., 2012; Elkhodairy et al., 2014; 
Shi et al., 2014).
In this scenario of microbial resistance, vancomycin (VAN) 
is considered a first-choice antibiotic for the treatment of 
methicillin-resistant S. aureus (MRSA) infections (Pumerantz 
et al., 2011; Honary et al., 2013; Holland et al., 2014; Men et al., 
2016; Gudiol et al., 2017). While VAN remains a first-choice 
antibiotic for the treatment of MRSA infections, its therapeutic 
efficacy is limited due to its high molecular weight (1,449.2 
g mol−1) and hydrophilicity restricting the drug interaction 
with bacterial cells and hindering its penetration into biofilms 
(Howden et al., 2010; Nicolosi et al., 2010; Butler et al., 2014; 
Moghadas-Sharif et al., 2015). In addition to that, VAN systemic 
side effects are another limiting factor, which include severe 
watery diarrhea, kidney failure (Pumerantz et al., 2011; Rose 
et al., 2012; Honary et al., 2013), ototoxicity, neutropenia, fever, 
anaphylaxis, thrombocytopenia, and phlebitis (McAuley, 2012).
Bacterial biofilms are characterized by the aggregation 
of specific bacterial species adhered to a substrate, forming 
highly organized microbial communities (Khameneh et al., 
2014; McCarthy et al., 2015). Biofilm-forming bacteria display 
a differentiated phenotype compared to planktonic cells and 
have the ability to produce an extracellular polymeric matrix 
composed mainly of polysaccharides (Khameneh et al., 2014; 
Dong et al., 2015; McCarthy et al., 2015). This scaffold provides an 
extremely robust defense mechanism, which hinders antibiotic 
penetration into the biofilm structure, substantially reducing the 
susceptibility of bacterial cells to exogenous agents (Dong et al., 
2015; McCarthy et al., 2015; Moghadas-Sharif et al., 2015).
The shortcomings of VAN traditional treatment along with the 
increased microbial resistance rates, and difficulty to treat biofilms 
have encouraged the development of drug-carrier systems such as 
VAN-loaded liposomal formulations (Kadry et al., 2004; Drulis-
Kawa et al., 2009; Nicolosi et al., 2010; Lankalapalli et al., 2015). 
It has been shown that the liposomal sustained release of VAN 
(i) enhances antibacterial efficacy due to higher interaction of the 
antibiotic molecule with bacterial cells (Kim and Jones, 2004); (ii) 
improves pharmacokinetics (Ma et al., 2011); (iii) reduces toxicity 
(Sande et al., 2012); and (iv) increases the antimicrobial spectrum 
of action against Gram-negative bacteria (Nicolosi et al., 2010). 
Furthermore, liposomes can facilitate antibiotic penetration into 
bacterial cells and, therefore, increase drug concentration in 
the biofilm inner layers (Moghadas-Sharif et al., 2015). Despite 
these reports, only a few studies have evaluated the effects of 
liposomal formulations on the inhibition of biofilm development 
and viability, particularly Staphylococcus biofilms (Ma et al., 2011; 
Moghadas-Sharif et al., 2015).
The liposome composition can be specifically modulated 
in terms of morphology to favor the adsorption onto, or 
fusion with, the microbial cell membrane. Likewise, vesicle 
surfaces can be changed based on the characteristics of the 
infectious agent (Nicolosi et al., 2010). Among some types of 
liposomes with the ability of interacting with bacterial biofilm 
cells are fusogenic and cationic liposomes (Kim et al., 1999; 
Nicolosi et al., 2010). Fusogenic liposomes are vesicles that 
may fuse with biological membranes, thereby increasing drug 
contact and delivery into cells. They consist of lipids, such as 
dioleoyl-phosphatidylethanolamine (DOPE) and cholesterol 
hemisuccinate (CHEMS), which provide increased fluidity to the 
lipid bilayer and may destabilize biological membranes (Nicolosi 
et al., 2010; Aoki et al., 2015; Nicolosi et al., 2015). Because of 
their composition, fusogenic liposomes are normally in the 
liquid crystalline phase and, under specific chemical conditions, 
e.g., acidic milieu or in the presence of cations (Forier et al., 
2014) they can lose the bilayer arrangement and fuse. Cationic 
liposomes are composed of lipids with a positive residual charge, 
such as stearylamine (SA), dimethyldioctadecylammonium 
bromide (DDBA), dimethylaminoethane carbamoyl cholesterol 
(DC-chol), and dioleoyltrimethylammoniumpropane (DOTAP), 
which provides specific electrostatic interaction with bacterial 
cell wall and biofilms, both negatively charged (Kim et al., 1999; 
Torchilin, 2012; Zhang et al., 2014; Moghadas-Sharif et al., 2015).
While fusogenic and cationic liposomes have proven 
advantages in interacting with bacterial cells and formed 
biofilms, there is still no consensus on the ideal composition 
of liposome-encapsulated VAN formulations able to prolong 
drug release and increase its antimicrobial efficacy. Thus, in the 
present study we developed and characterized large unilamellar 
vesicles of conventional (LUV VAN), fusogenic (LUVfuso 
VAN), and cationic (LUVcat VAN) liposomes encapsulating 
vancomycin hydrochloride. The in vitro antimicrobial activity 




VAN hydrochloride was kindly provided by Teuto/Pfizer 
Laboratory (Anápolis, GO, Brazil). HEPES buffer, cholesterol 
(Chol), alpha-tocopherol (α-T) and egg phosphatidylcholine 
(EPC) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA) and chloroform was obtained from Merck (Darmstadt, 
Germany). Dioleoylphosphatidylethanolamine (DOPE), 
dipalmitoylphosphatidylcholine (DPPC), cholesterol hemisuccinate 
(CHEMS) and stearylamine (Sa) were purchased from Avanti Polar 
Lipids Inc. (Alabaster, AL USA).
Preparation of Liposomal Formulations
Conventional (LUV VAN), fusogenic (LUVfuso VAN) and 
cationic (LUVcat VAN) liposomal formulations were prepared 
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containing 10 mg/ml VAN. Plain, VAN-free formulations were 
used as negative controls in the experiments (LUV, LUVfuso, and 
LUVcat). All liposomal formulations were prepared with 10 mM 
lipid concentration, with the following composition: LUV–EPC : 
Chol:α-T (4:3:0.07, mol%) (Cereda et al., 2006); LUVfuso–DOPE 
: DPPC : CHEMS:α-T (4:2:4:0.07, mol%) (Nicolosi et al., 2010); 
LUVcat–EPC : Sa:Chol:α-T (1:0.5:0.5:0.07, mol%) (Kadry et al., 
2004), respectively. All formulations were prepared in HEPES 
buffer (80 mM) containing 150 mM NaCl (pH 7.4).
Preparation of liposomal formulations was carried out as 
previously described, with modifications (Cereda et al., 2006). 
Briefly, the lipids were dissolved in chloroform, evaporated 
under nitrogen flow to obtain the lipid film, and vacuumed for 2 
h to ensure complete solvent removal. Subsequently, the film was 
hydrated in HEPES buffer with or without VAN hydrochloride 
solution. Then the suspension was vortexed for 5 min to form large 
multilamellar vesicles (MLVs). The suspensions were extruded 
under nitrogen flow at high pressure (Extruder Emulsiflex C5, 
Avestin, Inc., Ottawa, ON, Canada) 12 times using polycarbonate 
membrane initially with 400 nm pores, and then, with 100 nm 
pores, to obtain small unilamellar vesicles. The extrusion of 
LUVfuso formulation was performed in water bath at 50°C, which 
is higher than the DPPC phase transition temperature (Nicolosi 
et al., 2010).
Characterization of Liposomal 
Formulations
Morphological Analysis
The morphology of the different types of VAN-containing 
liposomes or plain liposomes was analyzed by Transmission 
Electron Microscopy (TEM) (906 LEO-ZEISS, Jena, Germany) 
at 80 kV. Briefly, one drop of each formulation was added to a 
copper-coated grid with 200 mesh for 10 s (Electron Microscopy 
Sciences, Fort Washington, PA). Subsequently, uranyl acetate 
aqueous solution (2%, w/v) was added and kept at room 
temperature for 4 h.
Determination of Size, Polydispersity Index, Zeta 
Potential and Stability of Liposomes
Liposomal vesicles were diluted in deionized water for evaluation 
of the average size (nm), polydispersity index (PDI), and zeta 
potential (mV) by the dynamic light scattering using Nano ZS 
equipment (Malvern Instruments Ltd., Worcestershire, UK, 
England) at 25°C in triplicate. To evaluate stability of liposomes, 
these parameters were monitored during 180 days at 4°C.
Vancomycin Encapsulation Efficiency
The encapsulation efficiency (%EE) of VAN into liposomal 
formulations was determined by the ultrafiltration–centrifugation 
method (Da Silva et al., 2016) (35). Unencapsulated VAN was 
separated from encapsulated VAN by ultracentrifugation 
(Optima L-90K Ultracentrifuge, Beckman Coulter Inc. Pasadena, 
California, USA) at 120,000g for 2 h at 10°C. Aliquots from 
the supernatant were diluted in deionized water and analyzed 
spectrophotometrically at 280 nm (Varian Cary® 50 UV-vis, 
Varian Inc., Palo Alto, CA, USA). The %EE was calculated 
based on the concentration of unencapsulated VAN over the 
concentration of VAN in solution, using the formula as follows:
 
% [ ] [ ]
[
EE VANsolution unencapsulated VAN
VANso
= − × 100
lution]  
Evaluation of Vancomycin Release In Vitro
The drug release assay was performed using the Franz 
vertical diffusion cell (Franz, 1975), which consists of two 
compartments—one donor and one receptor—separated by a 
regenerated cellulose membrane (Spectra/Por® 2) with molecular 
exclusion limit of 12,000–14,000 Da (Spectrum Laboratories 
Inc., Rancho Dominguez, CA, USA) (de Araujo et al., 2008; Da 
Silva et al., 2016). An aliquot of 1 ml of the liposomal suspensions 
was added to the donor compartment, while the receptor 
compartment was filled with 4 ml of buffer (pH 7.4), maintained 
at 37°C and 400 rpm agitation. Aliquots of the receptor medium 
were removed throughout the 10-hour experiment and analyzed 
by spectrophotometry at 280 nm (Varian Cary® 50 UV-Vis, 
Varian Inc., Palo Alto, CA, USA). The collected volume was 
replaced with fresh medium due to the dilution effect.
evaluation of Antimicrobial Activity
Microorganisms and Growth Conditions
Methicillin-susceptible S. aureus (MSSA) ATCC 29213 and 
methicillin-resistant S. aureus (MRSA) ATCC 43300 strains were 
used in this study. Microorganisms were maintained in Tryptone 
Soy Broth (TSB) (Difco®, New Jersey, USA) with 20% glycerol 
at −80°C, and cultivated onto Tryptone Soy Agar (Difco®, New 
Jersey, USA) plates at 37°C. Mueller Hinton Broth (MHB) (Difco®, 
New Jersey, USA) was used in the MIC assay, while Brain Heart 
Infusion (Difco®, New Jersey, USA) plus 1% D-glucose (Sigma-
Aldrich, St. Louis, MO, USA) was used in the biofilm killing assays.
Experimental Groups
Test formulations consisted of VAN-containing and VAN-free 
LUV, LUVfuso and LUVcat. The experimental groups were set as 
follows: A—culture medium, test formulation and inoculum; B—
culture medium, control formulation and inoculum; C—culture 
medium, free VAN solution and inoculum; D—culture medium, 
HEPES buffer (vehicle) and inoculum; E—culture medium and 
test formulation; F—culture medium and inoculum; and G—
culture medium alone.
Minimum Inhibitory Concentration (MIC)
The MIC was determined by the microdilution method, as 
previously described by the CLSI (2012), using Mueller-Hinton 
Broth. The formulations were added to 96-well microplates and 
serially diluted to obtain concentrations ranging from 0.025 
to 50 µg/ml. From 18–24 h agar cultures, three to five colonies 
of S.  aureus were dispersed into saline solution and bacterial 
inoculum was adjusted using a spectrophotometer (λ 625nm, OD 
0.1, 1 to 2 × 108 CFU/ml). Then, the inoculum was diluted and 
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transferred to the wells at a final concentration of 5 × 104 CFU/
ml. The plates were incubated at 37°C for 24 h and the absorbance 
was read at 620 nm (Biochrom ASYS UVM 340, Biochrom, 
Cambridge, England). The MIC was defined as the lowest 
concentration of the formulation which inhibited visible bacterial 
growth. The experiments were performed in six replicates.
Inhibitory Effects on Biofilm Formation
The liposomal formulations were tested for their ability to inhibit 
biofilm formation and adherence according to the protocol 
proposed by Graziano et al. (2015) and Wu et al. (2013). First, 
BHI medium supplemented with 1% glucose and S. aureus cell 
suspension (final concentration of 5 × 104 CFU/ml) were added to 
96-well U-bottom microplates. Right after, the test formulations 
were added to the wells and plates were then incubated for 24 h, 
at 37°C. After this period, the supernatant was removed, and the 
wells were washed three times with distilled water to remove 
loosely bound or non-adhered cells. Biofilms were stained 
with 0.4% crystal violet, solubilized with 98% ethanol and read 
in a microplate reader at 575 nm (Asys UVM 340, Biochrom, 
Cambridge, England).
Inhibitory Effects on Biofilm Viability
The liposomal formulations were next tested for their inhibitory 
effects on biofilm viability, as previously described (Graziano 
et al., 2015) (39). Cellulose acetate membranes (25 mm diameter, 
0.2 µM pores) (Sartorius Stedim GmbH, Guxhagen, Hessen, 
Germany) were used as substrates for S. aureus biofilm formation. 
The membranes were placed in 6-well plates containing BHI 
medium supplemented with 1% glucose and bacterial suspension 
(approximately 1 × 106 CFU/ml in each well). The plates were 
incubated at 37°C for 24 h. Then the membranes were transferred 
to new plates containing fresh BHI plus 1% glucose, and biofilms 
were treated with the formulations at 1 × MIC, 10 × MIC, and 
50 × MIC for 24 h. Treated biofilm-coated membranes were gently 
washed (three times) through immersion into 5 ml of 0.9% NaCl. 
Then, the membranes were transferred to other tubes containing 
freshly 5 ml of 0.9% NaCl and then sonicated with six pulses of 
9.9 s, 5 s time-interval, 5% amplitude (VibraCell 400W, Sonics & 
Materials Inc., Newtown, CT, USA) and vortexed at 3,800 rpm 
for 30 s. Ten-microliter aliquots were collected from each tube, 
serially diluted, and plated for CFUs onto TSA. The plates were 
incubated at 37°C for 24 h.
statistical Analysis
The data distribution was analyzed using the Shapiro–Wilks test. 
The variables size, PDI, zeta potential, and %EE, were compared 
using unpaired t-test. Stability parameters for liposomes and 
the biofilm data were compared using analysis of variance 
(ANOVA) followed by Tukey’s post-hoc test. The drug release 
profile was analyzed by two-way ANOVA followed by Tukey’s 
post-hoc test. Statistical analyses were performed on Origin 8.0 
(Microcal TM Software Inc., EUA) and GraphPad Prism 6.0 (San 
Diego, California, USA). The data were presented as mean and 
standard deviation (SD), with a 5% significance level. All data are 
representative of three independent experiments.
resULTs
Characterization of Liposomal 
Formulations
TEM images confirmed that the liposomal vesicles had 
spherical shape with clear edges. Vesicle size in all formulations 
ranged between 100 and 200 nm. Micrographs of all liposomal 
formulations are presented in Figure 1. As exemplified in Figures 
1C, D, some fusogenic vesicles were found to merge with each 
other, which typically characterizes this type of liposome.
The means and standard deviations of size, PDI, zeta potential 
and %EE of the liposomal formulations are given in Table 1. 
Comparisons were made between plain and VAN-containing 
liposomes. No differences in size were found while PDI values 
increased for VAN-containing formulations in comparison 
to plain controls (p < 0.05). Moreover, as expected, the zeta 
potential values confirmed the presence of negative charges on 
LUV and LUVfuso liposomes and positive charges on LUVcat. The 
encapsulation decreased the negative zeta potentials of LUVfuso 
VAN liposomes (p < 0.05), while it increased the positive zeta 
potential in LUVcat VAN, as compared to their respective controls 
(p < 0.05). Higher %EE values were observed for LUV VAN, 
followed by LUVfuso VAN and LUVcat VAN.
The stability of the formulations was determined from 
measurements of size, PDI and zeta potential (Figures 2A–C) 
during storage at 4°C. In general, LUVcat VAN, LUVfuso VAN and 
LUV VAN kept their size during the 180-day experimental period 
(p > 0.05). LUV VAN showed an increase in size after 7 days of 
storage (p < 0.05) but kept their size in the other time points. 
LUVcat VAN also changed in size after 60 and 90 days (p < 0.05). 
However, these alterations were no greater than 10% of the initial 
size. No significant changes in PDI and Zeta values were found 
during the experiment (p > 0.05). It is also worth noting that, 
although with an increasingly trend, PDI values were found to 
be under 0.2, as required for a monodisperse size distribution.
The release kinetics of VAN in solution and encapsulated in 
the liposomal formulations was determined in vitro. As seen in 
Figure 3, encapsulated VAN formulations showed prolonged 
releases overtime as compared to free VAN (p < 0.05).
The LUV VAN formulation showed slower release profile than 
the other liposomes (p < 0.05), whereas LUVfuso VAN and LUVcat 
VAN were found to have very similar release kinetics (p > 0.05). 
As expected, VAN-free formulations showed greater percent 
release at all timepoints, with a significant difference from the 
other liposomal formulations (p < 0.05).
Antimicrobial Activity
Free and encapsulated VAN LUV formulations affected bacterial 
growth in both MSSA (29213) and MRSA (43300) strains, with 
MIC values ranging between 0.78 and 1.56 µg/ml. These findings 
are in line with the information provided by the CLSI concerning 
S. aureus susceptibility to VAN (CLSI, 2012).
Next, the formulations were tested for their inhibitory 
effects on S. aureus ATCC 29213 biofilm adherence and 
formation. As shown in Figure 4, treatment with all 
formulations inhibited biofilm formation in a dose-dependent 
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fashion. Free VAN was found to inhibit biofilm formation at 
MIC (1.56 µg/ml) and higher concentrations as compared to 
the untreated biofilm control, while the inhibitory effects of 
liposome-encapsulated VAN were only seen from 2 × MIC 
(3.13 µg/ml).
These results corroborate those of the in vitro release kinetics 
assay (Figure 3), in which encapsulated VAN showed a late 
release profile as compared to free VAN. These can be attributed 
to the % amount of VAN encapsulated into the liposomes, so 
that just a fraction amount of VAN is available to immediately 
FIgUre 1 | TEM images of LUV VAN, LUVfuso VAN, and LUVca VAN.The left panel represents plain vesicles and the right panel indicated VAN-containing LUVs as 
follows: (A, B) LUV; (C, D) LUVfuso; and (e, F) LUVcat. Bars indicate 200 nm, with 100,000× magnification).
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act. Thus, it is likely that a lower amount of VAN molecules 
was initially released from the liposomal formulations, thereby 
slowing up their overall antimicrobial effects.
The inhibitory effects of the formulations on biofilm viability 
were also investigated. Figure 5 shows the mean (± SD) CFU/
ml (Log10) of biofilms treated for 24 h at 1 × MIC, 10 × MIC, 
and 50 × MIC. The data was compared among treatment groups 
and the untreated control. At 1 × MIC, only LUVcat VAN caused 
a significant decrease in the number of viable biofilm cells (p < 
0.01). Nevertheless, at 10 × MIC and 50 × MIC all formulations 
showed significant inhibitory effects as compared to the untreated 
control (p < 0.05). Free VAN was not able to affect biofilm 
viability significantly at 10 × MIC (p > 0.05), but it did at 50 × 
MIC (p < 0.05). When liposomal formulations were compared 
among themselves, we observed that LUVfuso VAN had the most 
noticeable inhibitory potential on mature biofilms, followed by 
LUVcat VAN and LUV VAN, with significant differences among 
them (p < 0.05).
The effects on mature biofilms treated with LUVcat VAN and 
free VAN were found to be similar at 50 × MIC (p > 0.05) and 
greater than those promoted by LUV VAN (p < 0.05). LUVfuso 
VAN was the most active formulation against S. aureus biofilm 
viability when compared to the other groups (p < 0.05). LUVfuso 
VAN reduced biofilm viability by 3.5 Log10 CFU/ml (35×); LUVcat 
VAN and free VAN caused a reduction of 2.5 Log10 CFU/ml 
(25×), while LUV VAN reduced biofilm viability by 1 log10 CFU/
ml (10×) in comparison to the control.
DIsCUssIOn
Nosocomial and community-acquired MRSA infections remain 
a major concern in global health and have driven the adoption of 
public policies and medical research in this field (Honary et al., 
2013; Elkhodairy et al., 2014; Holland et al., 2014). Evidence 
has shown the promising results of liposomal vesicles as drug 
carriers for pharmaceutical application (Kim et al., 1999; Nicolosi 
et al., 2010; Ma et al., 2011) (25, 26, 30). Herein, we report the 
development, characterization, and antimicrobial properties of 
experimental formulations containing VAN encapsulated into 
conventional, fusogenic and cationic liposomes. We compared 
the different formulations and demonstrated that the drug-
delivery liposomes were more active than VAN in solution in 
reducing mature biofilm, with better efficacy for LUVfuso VAN.
Our goal when selecting the liposomal formulations was 
to achieve greater interaction with bacterial cells and, thereby, 
facilitate penetration into mature biofilms. Conventional (LUV) 
TABLe 1 | Mean ( ± SD) of the size (nm), polydispersity index (PDI), zeta potential 









LUV 157.53 ± 2.58 0.09 ± 0.03 −19.2 ± 5.5 –
LUV VAn 152.60 ± 0.80 0.17 ± 0.01* −16.9 ± 0.5 32.5 ± 0.1
LUVfuso 161.87 ± 2.45 0.14 ± 0.02 −48.6 ± 4.9 –
LUVfuso VAn 153.37 ± 0.70 0.20 ± 0.01* −41.3 ± 2.3* 11.4 ± 0.1
LUVcat 130.97 ± 1.59 0.13 ± 0.01 50.6 ± 3.5
LUVcat VAn 139.73 ± 2.55 0.18 ± 0.02* 62.5 ± 5.6* 10.1 ± 0.1
The asterisk “*” indicates statistically significant difference between plain (LUV, 
LUVFUSO, LUVCAT) and their respective vancomycin-containing liposomes (LUV 
VAN, LUVFUSO VAN, LUVCAT VAN), p < 0.05 (unpaired t-test).
FIgUre 2 | Size (A), PDI (B) and Zeta potential (C) for VAN liposomal formulations analyses during 180 days. The asterisk “*” indicates statistically significant 
difference between the drug treatment and its respective untreated control at p < 0.05 (One-way ANOVA, followed by Tukey’s post-hoc test).
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FIgUre 3 | In vitro release kinetics of VAN in solution and encapsulated in the liposomal formulations, at 37°C. Two-way ANOVA, Tukey, P < 0.05. There were 
statistical difference between groups, as follows: LUV VAN × LUVfuso VAN—from 1 to 10 h; LUV VAN × LUVcat VAN—from 1 to 10h; LUV VAN × free VAN—from 0.15 
to 10 h; LUVfuso VAN × free VAN—from 0.15 to 8 h; LUVcat VAN × free VAN—from 0.15 to 8 h.
FIgUre 4 | Free and liposome-encapsulated VAN formulations for their inhibitory effects on S. aureus ATCC 29213 biofilm adherence. Mean ( ± SD) optical density values 
of S. aureus biofilms treated with different concentrations of VAN encapsulated into LUV VAN (A), LUVfuso VAN (B), LUVcat VAN (C), or free VAN solution (D). The asterisk “*” 
indicates statistically significant difference between the drug treatment and its respective untreated control at p < 0.05 (One-way ANOVA, followed by Tukey’s post-hoc test).
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liposomes contain a mixture of EPC and cholesterol, which 
increases the rigidity and stability of the vesicles (de Paula et al., 
2012). LUVfuso liposomes contain DOPE in their composition, 
which promotes destabilization of the lipid bilayer (towards 
inverse hexagonal structures) at acidic pH as it occurs in infected 
tissue. The use of DPPC was required for stabilization of the lipid 
bilayers due to the presence of DOPE. Additionally, EPC and 
CHEMS contribute to greater stability of the formulation (Aoki 
et al., 2015; Nicolosi et al., 2015). LUVcat liposomes contained 
stearylamine, EPC, and cholesterol in their composition. Sa is 
a positively charged lipid that facilitates, through electrostatic 
interactions, adsorption in the negatively charged bacterial 
biofilm (Balazs and Godbey, 2011). In order to prevent lipid 
oxidation, the antioxidant alpha-tocopherol was added to all 
liposomal formulations (de Paula et al., 2012).
The effect of VAN encapsulation was observed in changes 
in the Zeta values and size distribution in comparison to 
controls (Table 1). Such changes may have occurred because 
encapsulated VAN has a tendency to be located in the aqueous 
core or adjacent lipid-water interface near the polar head 
groups (Bozzuto and Molinari, 2015). This molecular location 
of VAN in liposomes could contribute to the reduction of size 
distribution homogeneity and enhance electrostatic attraction 
among liposomes, as VAN is positively charged. Similar 
results concerning vesicle size and PDI were also found 
with tetraether lipid liposomes (Uhl et al., 2017). Moreover, 
after 180 days of storage (4°C) the structural properties of 
the liposomes were maintained after VAN encapsulation, 
presenting desirable size and monodisperse distribution, as 
required for a drug delivery system.
LUV VAN and LUVcat VAN showed higher %EE (32.5% and 
10.1%, respectively) than those already reported (2.0% and 
5.0%, respectively) using equivalent (conventional, cationic) 
liposomes, but prepared by sonication and containing 20 mg/
ml VAN (Kadry et al., 2004). On the other hand, Nicolosi 
et al. (2010) observed greater %EE (65.8%) for fusogenic 
liposomes (prepared by the reverse-phase evaporation method) 
as compared to our findings (11.4%) (Nicolosi et al., 2010). 
According to the authors, the preparation method and drug 
concentration in the liposomal suspension may have influenced 
the high upload (Muppidi et al., 2012).
In this study, no significant difference was observed in the 
release kinetics of VAN-containing LUVfuso and LUVcat. Both 
formulations released 12% of VAN after 1 h, whereas LUV VAN 
released 2% and free VAN 33%. The differences in the drug 
controlled release profile among the liposomal formulations 
may be a result of their diverse %EE (Lankalapalli et al., 2015; 
Liu et al., 2015). Recently (Lankalapalli et al., 2015), evaluated 
the release kinetics of VAN from conventional liposomes 
EPC : Chol liposomes with VAN (10 mg/ml), prepared by the 
ethanol injection method. The authors observed similar results 
to those found in our study regarding VAN release from LUV 
VAN liposomes, and different results with regard to release of 
free VAN, which was about 42% after 22 h. This divergence 
may be related to the free VAN concentration used in the donor 
compartment, which was 100 mg/ml in the study by Lankalapalli 
et al. and 10 mg/ml in our study.
It is also known that VAN exerts antibacterial action by 
inhibiting the synthesis of cell wall peptidoglycans (Howden et 
al., 2010). This drug has a high affinity to the D-Ala-D-Ala residue 
from the peptidoglycan precursor, lipid II, thereby blocking 
the addition of final precursors by transglycosylation and 
transpeptidation, which ultimately interrupts cell wall formation. 
FIgUre 5 | The inhibitory effects of the formulations on biofilm viability. 
Inhibitory effects of liposomal and plain formulations on S. aureus ATCC 
29213 mature biofilm viability at 1 × MIC, 10 × MIC, and 50 × MIC. The 
values are expressed as mean ( ± SD) of CFU/ml. Different letters indicate 
significant differences between groups (p < 0.05 One-way ANOVA, with 
Tukey’s post-hoc test).
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In S. aureus, peptidoglycan biosynthesis takes place in the cell 
division septum in a specific site of the cytoplasmic membrane 
(Howden et al., 2010). Thus, in order to promote its effects on 
the cell wall, VAN molecules should penetrate approximately 
20 layers of peptidoglycan to reach the division septum and 
bind to the protein fraction (L-lysine-D-alanyl-D-alanine) of 
murein monomers used as a substrate for glycosyltransferases. 
Depending on the bacterial cell cycle phase, the division septum 
can be completely formed or under formation (Nicolosi et al., 
2010). Hence, the distance between the cell wall and the plasma 
membrane is shorter at the early phases of bacterial growth, 
which might have contributed to the bactericidal effects of free 
VAN. However, when bacterial growth reaches a final stage, the 
division septum is completely formed. As a result, the distance 
between the cell wall and the plasma membrane is wider, which 
may hinder the action of free VAN. In this case scenario, it is 
believed that encapsulated VAN could more effectively penetrate 
the cell wall and reach the periplasmic space, therefore promoting 
its antibacterial effects (Sande et al., 2012; Nicolosi et al., 2015). 
Such increased penetration can explain the improved antibiofilm 
activity observed in our study for the liposomal formulations.
The MIC values of liposome-encapsulated VAN on S. aureus 
ATCC 29213 observed in our study are in agreement with those 
found by Kadry et al. (2004). These authors reported MIC values 
of 0.75 µg/ml and 1.50 µg/ml for cationic and conventional 
liposomes, respectively. Another study found that encapsulation 
of VAN into conventional liposomes reduced by 2 the MIC against 
MRSA strains as compared to free VAN (Sande et al., 2012). 
This liposomal formulation was composed of DSPC : DCP:Chol 
(7:2:1, mol%) containing VAN at 50 mg/ml, which was 5 times 
higher than the VAN concentration used in our study.
Our findings indicate that free VAN at MIC had better 
inhibitory effects on early stages of biofilm formation than 
had the liposomal formulations. The latter inhibited biofilm 
adherence only from 2 × MIC, probably due to the encapsulation 
of vancomycin into the liposomes, with less free drug available to 
interact with forming biofilm. On the other hand, the liposomal 
formulations showed improved antibacterial activity than free 
VAN against mature biofilms, particularly LUVfuso VAN which 
was the most effective. Therefore, encapsulated VAN showed 
greater bactericidal effects on mature biofilms probably due to its 
increased ability to penetrate the peptidoglycan layers, whereas 
free VAN remained trapped in the cell wall.
Fusogenic liposomes have an increased potential to interact 
with extracellular matrix and cell wall due to their ability to merge 
with lipid membranes (Forier et al., 2014; Nicolosi et al., 2015). 
These vesicles are composed of lipids that promote destabilization 
of the lipid bilayers (Forier et al., 2014) and their fusion with the 
bacterial cell wall was previously proved through flow cytometry, 
lipid-mixing assay, electronic transmission microscopy and 
immunochemistry (Beaulac et al., 1998; Sachetelli et al., 2000; 
Forier et al., 2014; Wang et al., 2016). These vesicles can pass 
through the cell wall and deliver VAN into the periplasmic space, 
thereby making it easier for the drug to reach the division septum 
and block peptidoglycan biosynthesis (Howden et al., 2010; Sande 
et al., 2012; Nicolosi et al., 2015). Besides, cationic liposomes may 
have a higher affinity for negatively charged biofilms, which can 
decrease VAN delivery time into the infectious focus (Kim et al., 
1999; Kadry et al., 2004). Accordingly, these liposomes probably 
release VAN in the vicinities of the bacterial cell wall due to the 
affinity with its negative charge, resulting in inhibition of cell wall 
biosynthesis.
There are other studies with VAN-loaded liposomal 
formulations (Ma et al., 2011; Barakat et al., 2014), but very few 
tested the ability in inhibit or eradicate S. aureus biofilm, which 
is a more resistant form of growth and much less sensitive to 
antibiotics. In the present study, we compared two formulations 
that are claimed to be effective against bacterial growth: fusogenic 
and cationic vesicles. Both formulations were effective in reducing 
mature biofilm, but with superiority to fusogenic vesicles.
To the best of the author´s knowledge, there are only two studies 
that encapsulate vancomycin into fusogenic liposomes (Nicolosi 
et al., 2010; Garcia et al., 2017), but none of them tested the activity 
against S. aureus. In addition, there are other non-fusogenic 
VAN-loaded liposomes that were tested against S. aureus, but 
very few aimed to test against biofilm (Ma et al., 2011; Barakat et 
al., 2014). Other drug delivery systems have also been proposed 
to improve drug delivery at sites of infection and to overcome 
antimicrobial resistance, such as injectable and biodegradable 
hydrogels (Zhao et al., 2017; Qu et al., 2018; Liang et al., 2019; Qu 
et al., 2019), polymeric nanoparticles (Lakshminarayanan et al., 
2018), metal-based nanoparticles (Brown et al., 2012; Noronha et 
al., 2017), carbon-based nanoparticles (Zhao et al., 2017; Jiang et 
al., 2018), etc. Contributing to the development and comparison 
of antibiotics delivery systems, the present study showed that the 
liposomes here tested can reduce the formation and viability of 
mature biofilm, in a way superior to free vancomycin.
COnCLUsIOn
We demonstrated the successful development, characterization 
and stability of LUV, LUVfuso and LUVcat encapsulated VAN 
formulations. Liposomes improved the antimicrobial activity 
of vancomycin against S. aureus biofilm, with better efficacy 
for fusogenic vesicles. Future studies are needed to validate this 
formulation as a candidate for S. aureus infection control.
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